Results 31 to 40 of about 4,204,588 (241)

B Cell-Based Seamless Engineering of Antibody Fc Domains. [PDF]

PLoS ONE, 2016
Engineering of monoclonal antibodies (mAbs) enables us to obtain mAbs with additional functions. In particular, modifications in antibody's Fc (fragment, crystallizable) region can provide multiple benefits such as added toxicity by drug conjugation ...
Koji Hashimoto, Kohei Kurosawa, Akiho Murayama, Hidetaka Seo, Kunihiro Ohta   +4 more
doaj   +1 more source

Biological Active Region Defined by Fragment-based Molecular Theory [PDF]

Computational chemistry studies using the QM/MM approach have been conducted to explain and predict protein functions. However, the active regions responsible for those functions often need to be clarified.
Hirotoshi, Mori, Nichika, Ozawa, Nahoko, Kuroki   +2 more
core   +1 more source

Transient proteolysis reduction of Nicotiana benthamiana-produced CAP256 broadly neutralizing antibodies using CRISPR/Cas9

Frontiers in Plant Science, 2022
The hypersensitive response is elicited by Agrobacterium infiltration of Nicotiana benthamiana, including the induction and accumulation of pathogenesis-related proteins, such as proteases.
Advaita Acarya Singh, Advaita Acarya Singh, Priyen Pillay, Previn Naicker, Kabamba Alexandre, Kanyane Malatji, Lukas Mach, Herta Steinkellner, Juan Vorster, Rachel Chikwamba, Tsepo L. Tsekoa   +10 more
doaj   +1 more source

Neospora caninum as delivery vehicle for anti-PD-L1 scFv-Fc: A novel approach for cancer immunotherapy

Molecular Therapy: Oncology
Neospora caninum, a potential anticancer agent able to reactivate the immune response within the tumor microenvironment (TME), has recently shown enhanced immunomodulatory properties in different tumor models when armed with the cytokine, Il-15.
Clément Riviere, Muna Aljieli, Marie-Noëlle Mévélec, Louis Lantier, Fanny Boursin, Laurie Lajoie, Céline Ducournau, Stéphanie Germon, Nathalie Moiré, Isabelle Dimier-Poisson, Nicolas Aubrey, Anne di Tommaso   +11 more
doaj   +1 more source

Fragment-Based Identification of Influenza Endonuclease Inhibitors [PDF]

, 2016
The influenza virus is responsible for millions of cases of severe illness annually. Yearly variance in the effectiveness of vaccination, coupled with emerging drug resistance, necessitates the development of new drugs to treat influenza infections.
Credille, Cy V, Cohen, Seth M, Yao Chen, Yao Chen (149006), Cy V. Credille, Cy V. Credille (2849522), Chen, Yao, Seth M. Cohen (1271355), Seth M. Cohen   +8 more
core   +1 more source

Conserved binding mode but diverse interfaces of MreC‐PBP2 interactions

FEBS Letters, EarlyView.
The crystal structure of abMreC reveals a conserved two β‐barrel architecture and provides structural insights into its role within the bacterial elongasome. The abMreC–abPBP2 complex model identifies the molecular basis of MreC‐mediated PBP2 recognition, contributing to the regulation of peptidoglycan synthesis.
Hyunseok Jang, Hyo Been Jin, Chang Min Kim, So Yeon Lee, Hyun Ho Park   +4 more
wiley   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV

Pharmaceutics
Monoclonal antibodies are commonly engineered with an introduction of Met428Leu and Asn434Ser, known as the LS mutation, in the fragment crystallizable region to improve pharmacokinetic profiles.
Bryan T. Mayer, Lily Zhang, Allan C. deCamp, Chenchen Yu, Alicia Sato, Heather Angier, Kelly E. Seaton, Nicole Yates, Julie E. Ledgerwood, Kenneth Mayer, Marina Caskey, Michel Nussenzweig, Kathryn Stephenson, Boris Julg, Dan H. Barouch, Magdalena E. Sobieszczyk, Srilatha Edupuganti, Colleen F. Kelley, M. Juliana McElrath, Huub C. Gelderblom, Michael Pensiero, Adrian McDermott, Lucio Gama, Richard A. Koup, Peter B. Gilbert, Myron S. Cohen, Lawrence Corey, Ollivier Hyrien, Georgia D. Tomaras, Yunda Huang   +29 more
doaj   +1 more source

Fragment-Based Design of Mycobacterium tuberculosis InhA Inhibitors

, 2020
Tuberculosis (TB) remains a leading cause of mortality among infectious diseases worldwide. InhA has been the focus of numerous drug discovery efforts as this is the target of the first line pro-drug isoniazid.
Robert G. Vistal (8714796), Jana Korduláková (1371816), David M. G. Dias (8714799), Anthony G. Coyne (1973287), Monika Záhorszká (8714802), Katarína Mikušová (1446046), Tom L. Blundell (53804), Chris Abell (197099), Vitor Mendes (6210233), Mohamad Sabbah (1923403)   +9 more
core   +2 more sources

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source